Gesynta Pharma today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis - a chronic inflammatory condition affecting approximately 10 percent of women of reproductive age. This strategic move follows a recent preclinical proof-of-concept study, where GS-248 demonstrated remarkable disease-modifying properties in an advanced endometriosis model. Coupled with the drug's previously established favorable clinical safety profile and the substantial unmet medical need, these findings serve as the foundation for the initiation of preparations for a Phase II study in endometriosis.
Endometriosis, an estrogen-driven chronic inflammatory disease, is characterized by the presence of tissue resembling the uterine lining outside the uterus. It triggers a chronic inflammatory response that can lead to the formation of scar tissue (adhesions and fibrosis) in the pelvis and other areas of the body. This condition afflicts approximately 190 million women worldwide, with symptoms typically emerging in the teenage years or early twenties.
Women with endometriosis suffer greatly from severe pelvic pain, dysmenorrhea, pain on defecation and urination, and painful sexual intercourse. The disease is also closely associated with reduced fertility. Due to the enduring high disease burden, it significantly impairs overall quality of life.
For further details, please see the press release.
Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.
Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.
Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.
Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.